Batten Disease CLN1

Disease Overview

Batten Disease CLN1 is a rare, fatal, inherited neurodegenerative disorder characterized by progressive neurological deterioration. It typically begins in early childhood, causing severe neurological decline, seizures, vision loss, and developmental regression.

Disease Category

Neurodegenerative lysosomal storage disorder; specifically a type of Neuronal Ceroid Lipofuscinosis (NCL)

Synonyms

• Infantile Neuronal Ceroid Lipofuscinosis (INCL)
• CLN1 disease
• Santavuori-Haltia disease
• PPT1-related neuronal ceroid lipofuscinosis

Signs & Symptoms

• Early developmental delay (6 months to 2 years)
• Progressive neurological symptoms:
  • Intractable seizures
  • Rapid motor skill deterioration
  • Complete vision loss
  • Cognitive decline
  • Muscle rigidity and spasticity
  • Loss of speech and communication abilities
  • Profound intellectual disability
  • Feeding difficulties
  • Eventual complete loss of motor function

Causes

• Genetic Mutation: Pathogenic variants in the PPT1 gene
• Inheritance Pattern: Autosomal recessive
• Results in deficiency of palmitoyl-protein thioesterase-1 enzyme
• Leads to abnormal protein and lipid storage in cells

Affected Populations

• Incidence: Approximately 1 in 100,000 live births
• Onset: Typically between 6 months and 2 years of age
• Equal prevalence in males and females
• Most common in populations of Northern European descent

Disorders with Similar Symptoms

• Other Neuronal Ceroid Lipofuscinoses (CLN2-CLN14)
• Rett Syndrome
• Mitochondrial disorders
• Leukodystrophies
• Metabolic storage disorders

Diagnosis

• Genetic testing for PPT1 gene mutations
• Enzyme activity assay for palmitoyl-protein thioesterase-1
• Brain MRI showing characteristic neurodegeneration
• EEG to document seizure patterns
• Visual evoked potential testing
• Skin or muscle biopsy to detect characteristic cellular inclusions

Standard Therapies

• Symptomatic management:
  • Anticonvulsant medications
  • Physical therapy
  • Occupational therapy
  • Nutritional support
  • Respiratory care
• Experimental approaches:
  • Gene therapy
  • Enzyme replacement therapy
  • Stem cell research

Clinical Trials and Studies

• Ongoing research at major pediatric neurology centers
• Gene therapy trials investigating PPT1 gene correction
• Enzyme replacement therapy studies
• Registered clinical trials available on ClinicalTrials.gov

References

• Online Mendelian Inheritance in Man (OMIM)
• National Organization for Rare Disorders (NORD)
• Genetic and Rare Diseases Information Center
• Recent genetic and neurological research publications

Programs & Resources

• Batten Disease Support and Research Association (BDSRA)
• National Institute of Neurological Disorders and Stroke (NINDS)
• International NCL Research Consortium
• Genetic counseling services
• Patient support groups

Complete Report

Comprehensive management requires a multidisciplinary approach involving neurologists, geneticists, pediatric specialists, and supportive care teams. Early diagnosis and comprehensive care are crucial for managing symptoms and improving quality of life.